<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Almanac of Clinical Medicine</journal-id><journal-title-group><journal-title xml:lang="en">Almanac of Clinical Medicine</journal-title><trans-title-group xml:lang="ru"><trans-title>Альманах клинической медицины</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2072-0505</issn><issn publication-format="electronic">2587-9294</issn><publisher><publisher-name xml:lang="en">Moscow Regional Research and Clinical Institute (MONIKI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1774</article-id><article-id pub-id-type="doi">10.18786/2072-0505-2023-51-033</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Clinical particulars of acute coronary syndrome course in patients with COVID-19</article-title><trans-title-group xml:lang="ru"><trans-title>Клинические особенности вариантов течения острого коронарного синдрома у пациентов с COVID-19</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7826-9657</contrib-id><contrib-id contrib-id-type="scopus">19337559100</contrib-id><contrib-id contrib-id-type="researcherid">AAI-1947-2020</contrib-id><contrib-id contrib-id-type="spin">4738-3269</contrib-id><name-alternatives><name xml:lang="en"><surname>Izmozherova</surname><given-names>Nadezhda V.</given-names></name><name xml:lang="ru"><surname>Изможерова</surname><given-names>Надежда Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Associate Professor, Head of Chair of Pharmacology and Clinical Pharmacology</p></bio><bio xml:lang="ru"><p>д-р мед. наук, доцент, заведующая кафедрой фармакологии и клинической фармакологии</p></bio><email>nadezhda_izm@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6216-2468</contrib-id><contrib-id contrib-id-type="scopus">24390984000</contrib-id><contrib-id contrib-id-type="researcherid">P-5147-2015</contrib-id><contrib-id contrib-id-type="spin">5083-9389</contrib-id><name-alternatives><name xml:lang="en"><surname>Popov</surname><given-names>Artem A.</given-names></name><name xml:lang="ru"><surname>Попов</surname><given-names>Артем Анатольевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Associate Professor, Head of Chair of Hospital Therapy and Urgent Medical Care Service</p></bio><bio xml:lang="ru"><p>д-р мед. наук, доцент, заведующий кафедрой госпитальной терапии и скорой медицинской помощи</p></bio><email>art_popov@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8751-6872</contrib-id><contrib-id contrib-id-type="spin">7081-0400</contrib-id><name-alternatives><name xml:lang="en"><surname>Tsvetkov</surname><given-names>Andrey I.</given-names></name><name xml:lang="ru"><surname>Цветков</surname><given-names>Андрей Игоревич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Head of Chair of Public Health Service</p></bio><bio xml:lang="ru"><p>д-р мед. наук, заведующий кафедрой общественного здоровья и здравоохранения</p></bio><email>cp-gendir@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2623-2657</contrib-id><contrib-id contrib-id-type="scopus">57890780200</contrib-id><contrib-id contrib-id-type="researcherid">AEQ-9096-2022</contrib-id><contrib-id contrib-id-type="spin">2283-2100</contrib-id><name-alternatives><name xml:lang="en"><surname>Kadnikov</surname><given-names>Leonid I.</given-names></name><name xml:lang="ru"><surname>Кадников</surname><given-names>Леонид Игоревич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Postgraduate Student, Chair of Pharmacology and Clinical Pharmacology</p></bio><bio xml:lang="ru"><p>аспирант кафедры фармакологии и клинической фармакологии</p></bio><email>kadn-leonid@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8152-6474</contrib-id><contrib-id contrib-id-type="spin">8918-8411</contrib-id><name-alternatives><name xml:lang="en"><surname>Ispavskii</surname><given-names>Vladislav E.</given-names></name><name xml:lang="ru"><surname>Испавский</surname><given-names>Владислав Евгеньевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Postgraduate Student, Chair of Pharmacology and Clinical Pharmacology</p></bio><bio xml:lang="ru"><p>аспирант кафедры фармакологии и клинической фармакологии</p></bio><email>ispavsky@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7312-415X</contrib-id><contrib-id contrib-id-type="scopus">57216921642</contrib-id><contrib-id contrib-id-type="spin">6693-5347</contrib-id><name-alternatives><name xml:lang="en"><surname>Shambatov</surname><given-names>Muraz A.</given-names></name><name xml:lang="ru"><surname>Шамбатов</surname><given-names>Мураз Акбар оглы</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Postgraduate Student, Chair of Pharmacology and Clinical Pharmacology</p></bio><bio xml:lang="ru"><p>аспирант кафедры фармакологии и клинической фармакологии</p></bio><email>shambatovma@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Ural State Medical University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Уральский государственный медицинский университет» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2023-11-10" publication-format="electronic"><day>10</day><month>11</month><year>2023</year></pub-date><pub-date date-type="pub" iso-8601-date="2023-11-17" publication-format="electronic"><day>17</day><month>11</month><year>2023</year></pub-date><volume>51</volume><issue>5</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>290</fpage><lpage>300</lpage><history><date date-type="received" iso-8601-date="2022-12-28"><day>28</day><month>12</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-10-30"><day>30</day><month>10</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Izmozherova N.V., Popov A.A., Tsvetkov A.I., Kadnikov L.I., Ispavskii V.E., Shambatov M.A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Изможерова Н.В., Попов А.А., Цветков А.И., Кадников Л.И., Испавский В.Е., Шамбатов М.А.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Izmozherova N.V., Popov A.A., Tsvetkov A.I., Kadnikov L.I., Ispavskii V.E., Shambatov M.A.</copyright-holder><copyright-holder xml:lang="ru">Изможерова Н.В., Попов А.А., Цветков А.И., Кадников Л.И., Испавский В.Е., Шамбатов М.А.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://almclinmed.ru/jour/article/view/1774">https://almclinmed.ru/jour/article/view/1774</self-uri><abstract xml:lang="en"><p><bold>Background</bold>: Cardiovascular complications of COVID-19 result in challenges for differential diagnosis, patient’s referral and treatment, which negatively affect the outcomes.</p> <p><bold>Aim</bold>: To identify clinical particulars of various types acute coronary syndrome course in patients with COVID-19.</p> <p><bold>Materials and methods</bold>: This retrospective cross-sectional study included 202 patients with COVID-19 and acute coronary syndrome (ACS) admitted to a primary vascular medicine center from September to December 2020. Their medical records were used for the analysis of ACS and COVID-19 clinical course, including physical and history data, laboratory and instrumental work-up. For the analysis, the patient sampling was divided into three study groups: 50 patients with unstable angina (UA), 107 patients with acute myocardial infarction with ST segment elevation (STEMI), and 45 patients with acute myocardial infarction without ST segment elevation (non-STEMI).</p> <p><bold>Results</bold>: There were no differences in clinical manifestations of ACS in the study groups. As far as clinical manifestations of coronavirus infections are concerned, the patients differed significantly as per prevalence of fever and dry cough. Fever was present in 22 (44%) UA patients, 18 (17%) of STEMI patients and in 10 (22%) of non-STEMI patients (p &lt; 0.001 for comparison of 3 groups, Kruskall-Wallis test), whereas dry cough was present in 18 (36%), 19 (18%), and 14 (31%) patients, respectively (p = 0.029). Paired comparison (Mann-Whitney test with Bonferroni adjustment) showed significant differences between US and STEMI groups for both symptoms. The number of involved vessels (median [25%; 75%]) in UA patients was 0 [0; 2], in STEMI and non-STEMI patients 2 [1; 3] (p &lt; 0.001). A left coronary artery stenosis was detected in 2 (6%) of the UA patients, 13 (14%) of the STEMI and 4 (13%) of the non-STEMI patients (p = 0.452); left anterior descending artery stenosis, in 12 (36%), 67 (72%) and 23 (72%) patients, respectively (p &lt; 0.001). In the pairwise comparison, there were differences between UA and STEMI groups and between UA and non-STEMI groups. A left circumflex artery stenosis was found in 7 (21%) of the UA patients, 45 (48%) of the STEMI and 18 (56%) of the non-STEMI patients (p = 0.008); the pairwise comparisons showed the difference between UA and non-STEMI study groups. A right coronary artery stenosis was identified in 9 (27%), 64 (69%) and 18 (56%) of the study patients, respectively (p &lt; 0.001); in the pairwise comparison the difference was found between the UA and STEMI group. There were significant differences in the percentage of the right descendent and right coronary artery stenosis: the right descending artery stenosis was 70% [45; 80] in the UA patients, 90% [70; 100] in the STEMI and 95% [70; 100] in the non-STEMI patients (p = 0.013), whereas the right coronary artery stenosis was 50% [45; 80], 90% [70; 100], 90% [60; 100], respectively (p = 0.018). In the pairwise comparison, the differences were found between the UA and STEMI patients in both arteries. The STEMI patients had higher TIMI thrombus grade scores than those with non-STEMI: 3 [0; 5] vs 0 [0; 4] (p = 0.023). The rates of successful percutaneous coronary intervention and achievement of TIMI flow grade 3 between them was not significantly different (p = 0.170).</p> <p><bold>Conclusion</bold>: The ACS patients with ACS and COVID-19 have high thrombotic load according to coronary angiography and TIMI score in the case of STEMI and more frequent absence of hemodynamically significant stenosis in those with UA and non-STEMI. The absence of any difference in clinical manifestations of ACS and viral infection between the study groups (except fever and dry cough difference between the UA and STEMI patients) indicates that specific characteristics of the ACS course in COVID-19 patients can be identified only by coronaroangiography.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Актуальность</bold>. Сердечно-сосудистые осложнения COVID-19 приводят к трудностям в дифференциальной диагностике, маршрутизации и лечении, негативно влияя на прогноз.</p> <p><bold>Цель</bold> – выявить клинические особенности вариантов течения острого коронарного синдрома (ОКС) у пациентов с COVID-19.</p> <p><bold>Материал и методы</bold>. В одномоментное ретроспективное исследование включены 202 пациента, госпитализированных в первичный сосудистый центр в период с сентября по декабрь 2020 г. по поводу ОКС, развившегося на фоне COVID-19. По данным медицинских карт стационарных больных проводили анализ клинической картины ОКС и COVID-19, а также физикальных, лабораторных, инструментальных, анамнестических данных. В целях анализа выборку разделили на 3 группы: 50 пациентов с нестабильной стенокардией (НС), 107 пациентов с острым инфарктом миокарда с подъемом сегмента ST (ИМпST), 45 пациентов с острым инфарктом миокарда без подъема сегмента ST (ИМбпST).</p> <p><bold>Результаты</bold>. Клиническая картина ОКС не различалась среди пациентов исследуемых групп. Что касается основных клинических проявлений со стороны коронавирусной инфекции, пациенты статистически значимо различались по наличию лихорадки и сухого кашля: лихорадку регистрировали у 22 (44%) пациентов в группе НС, у 18 (17%) в группе ИМпST, у 10 (22%) в группе ИМбпST (p &lt; 0,001 при сравнении 3 групп, критерий Краскела – Уоллиса); сухой кашель – у 18 (36%), 19 (18%) и 14 (31%) пациентов соответственно (p = 0,029); при парном сравнении (критерий Манна – Уитни с поправкой Бонферрони) различия выявлены между группами НС и ИМпST в обоих случаях. Количество пораженных сосудов (Me [25%; 75%] у пациентов с НС составило 0 [0; 2], у больных с ИМпST и ИМбпST по 2 [1; 3] пораженных артерии (p &lt; 0,001). Стеноз левой коронарной артерии выявлен у 2 (6%) пациентов в группе НС, у 13 (14%) в группе ИМпST и у 4 (13%) – в ИМбпST (p = 0,452); стеноз передней нисходящей артерии – у 12 (36%), 67 (72%) и 23 (72%) пациентов соответственно (p &lt; 0,001); при парном сравнении различия обнаружены между группами НС и ИМпST, между группами НС и ИМбпST. Стеноз огибающей артерии выявлен у 7 (21%) пациентов в группе НС, у 45 (48%) в группе ИМпST и у 18 (56%) в группе ИМбпST (p = 0,008); при парном сравнении различия выявлены между группами НС и ИМбпST. Стеноз правой коронарной артерии отмечен у 9 (27%), 64 (69%) и 18 (56%) пациентов соответственно (p &lt; 0,001), при парном сравнении различия выявлены между группами НС и ИМпST. По поражению коронарных артерий в диаметре статистически значимо различались правая нисходящая и правая коронарная артерии: стеноз правой нисходящей составил 70% [45; 80] в группе НС, 90% [70; 100] в группе ИМпST и 95% [70; 100] в группе ИМбпST (p = 0,013); стеноз правой коронарной артерии – 50% [45; 80], 90% [70; 100] и 90% [60; 100] пациентов соответственно (p = 0,018); при парном сравнении различия выявлены между группами НС и ИМпST в обеих артериях. Пациенты с ИМпST имели больший балл по шкале TIMI thrombus grade, чем пациенты из группы ИМбпST: 3 [0; 5] против 0 [0; 4] баллов (p = 0,023); частота успешного чрескожного коронарного вмешательства и достижение кровотока TIMI flow grade 3 между ними не различались (p = 0,170).</p> <p><bold>Заключение</bold>. У больных с ОКС и COVID-19 выявлены высокая тромботическая нагрузка по данным коронарографии и шкале TIMI при ИМпST, более частое отсутствие гемодинамически значимых стенозов при НС и ИМбпST. Отсутствие различий в клинической картине ОКС и проявлениях вирусной инфекции между исследуемыми группами, за исключением лихорадки и сухого кашля между пациентами с НС и пациентами с ИМпST, указывает на наличие отличительных особенностей вариантов течения ОКС при COVID-19 только по данным коронарографии.</p></trans-abstract><kwd-group xml:lang="en"><kwd>new coronavirus disease</kwd><kwd>COVID-19</kwd><kwd>unstable angina</kwd><kwd>myocardial infarction</kwd><kwd>ST elevation</kwd><kwd>clinical manifestations</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>новая коронавирусная инфекция</kwd><kwd>COVID-19</kwd><kwd>нестабильная стенокардия</kwd><kwd>инфаркт миокарда</kwd><kwd>подъем сегмента ST</kwd><kwd>клиническая картина</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Azevedo RB, Botelho BG, Hollanda JVG, Ferreira LVL, Junqueira de Andrade LZ, Oei SSML, Mello TS, Muxfeldt ES. Covid-19 and the cardiovascular system: a comprehensive review. J Hum Hypertens. 2021;35(1):4–11. doi: 10.1038/s41371-020-0387-4.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol. 2020;17(9):543–558. doi: 10.1038/s41569-020-0413-9.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi: 10.1016/0021-9681(87)90171-8.</mixed-citation></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Barbarash OL, Duplyakov DV, Zateischikov DA, Panchenko EP, Shakhnovich RM, Yavelov IS, Yakovlev AN, Abugov SA, Alekyan BG, Arkhipov MV, Vasilieva EYu, Galyavich AS, Ganyukov VI, Gilyarevskyi SR, Golubev EP, Golukhova EZ, Gratsiansky NA, Karpov YuA, Kosmacheva ED, Lopatin YuM, Markov VA, Nikulina NN, Pevzner DV, Pogosova NV, Protopopov AV, Skrypnik DV, Tereshchenko SN, Ustyugov SA, Khripun AV, Shalaev SV, Shpektor VA, Yakushin SS. [2020 Clinical practice guidelines for Acute coronary syndrome without ST segment elevation]. Russian Journal of Cardiology. 2021;26(4):4449. Russian. doi: 10.15829/1560-4071-2021-4449.</mixed-citation><mixed-citation xml:lang="ru">Барбараш ОЛ, Дупляков ДВ, Затейщиков ДА, Панченко ЕП, Шахнович РМ, Явелов ИС, Яковлев АН, Абугов СА, Алекян БГ, Архипов МВ, Васильева ЕЮ, Галявич АС, Ганюков ВИ, Гиляревский СР, Голубев ЕП, Голухова ЕЗ, Грацианский НА, Карпов ЮА, Космачева ЕД, Лопатин ЮМ, Марков ВА, Никулина НН, Певзнер ДВ, Погосова НВ, Протопопов АВ, Скрыпник ДВ, Терещенко СН, Устюгов СА, Хрипун АВ, Шалаев СВ, Шпектор АВ, Якушин СС. Острый коронарный синдром без подъема сегмента ST электрокардиограммы. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(4):4449. doi: 10.15829/1560-4071-2021-4449.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><mixed-citation>Tajbakhsh A, Gheibi Hayat SM, Taghizadeh H, Akbari A, Inabadi M, Savardashtaki A, Johnston TP, Sahebkar A. COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up. Expert Rev Anti Infect Ther. 2021;19(3):345–357. doi: 10.1080/14787210.2020.1822737.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Barstow C, Rice M, McDivitt JD. Acute Coronary Syndrome: Diagnostic Evaluation. Am Fam Physician. 2017;95(3):170–177.</mixed-citation></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">2020 Clinical practice guidelines for Acute ST-segment elevation myocardial infarction. Russian Journal of Cardiology. 2020;25(11):4103. Russian. doi: 10.15829/1560-4071-2020-4103.</mixed-citation><mixed-citation xml:lang="ru">Российское кардиологическое общество, Ассоциация сердечно-сосудистых хирургов России. Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4103. doi: 10.15829/1560-4071-2020-4103.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Volovchenko AN, Giliarov MYu, Syrkin AL. [Causes for elevated troponin level unrelated to acute coronary syndrome and heart failure]. Kardiologiya i serdechno-sosudistaya khirurgiya [Cardiology and Cardiovascular Surgery]. 2012;5(3):18–25. Russian.</mixed-citation><mixed-citation xml:lang="ru">Воловченко АН, Гиляров МЮ, Сыркин АЛ. Причины повышения уровня тропонина, не связанные с острым коронарным синдромом и сердечной недостаточностью. Кардиология и сердечно-сосудистая хирургия. 2012;5(3):18–25.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><mixed-citation>Mueller C, Giannitsis E, Jaffe AS, Huber K, Mair J, Cullen L, Hammarsten O, Mills NL, Möckel M, Krychtiuk K, Thygesen K, Lindahl B; ESC Study Group on Biomarkers in Cardiology of the Acute Cardiovascular Care Association. Cardiovascular biomarkers in patients with COVID-19. Eur Heart J Acute Cardiovasc Care. 2021;10(3):310–319. doi: 10.1093/ehjacc/zuab009.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19. Am J Emerg Med. 2020;38(7):1504–1507. doi: 10.1016/j.ajem.2020.04.048.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J, Zhao Q, Huang H, Yang B, Huang C. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802–810. doi: 10.1001/jamacardio.2020.0950.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Li L, Zhou Q, Xu J. Changes of Laboratory Cardiac Markers and Mechanisms of Cardiac Injury in Coronavirus Disease 2019. Biomed Res Int. 2020;2020:7413673. doi: 10.1155/2020/7413673.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Hamm CW, Braunwald E. A classification of unstable angina revisited. Circulation. 2000;102(1):118–122. doi: 10.1161/01.cir.102.1.118.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Mafham MM, Spata E, Goldacre R, Gair D, Curnow P, Bray M, Hollings S, Roebuck C, Gale CP, Mamas MA, Deanfield JE, de Belder MA, Luescher TF, Denwood T, Landray MJ, Emberson JR, Collins R, Morris EJA, Casadei B, Baigent C. COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England. Lancet. 2020;396(10248):381–389. doi: 10.1016/S0140-6736(20)31356-8.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Cammann VL, Templin C. The STEMI phenomenon during the COVID-19 pandemic: what is beneath the tip of the iceberg? Heart. 2022;108(6):412–413. doi: 10.1136/heartjnl-2021-320383.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Alasnag M, Shah B, Botti G, Zaman S, Chieffo A. STEMIs and a Closer Look at MINOCA During the COVID-19 Pandemic. J Soc Cardiovasc Angiogr Interv. 2022;1(4):100372. doi: 10.1016/j.jscai.2022.100372.</mixed-citation></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Chashchin MG, Gorshkov AYu, Drapkina OM. [Acute coronary syndrome in COVID-19 patients]. Cardiovascular Therapy and Prevention. 2021;20(5):2806. Russian. doi: 10.15829/1728-8800-2021-2806.</mixed-citation><mixed-citation xml:lang="ru">Чащин МГ, Горшков АЮ, Драпкина ОМ. Острый коронарный синдром у пациентов с COVID-19. Кардиоваскулярная терапия и профилактика. 2021;20(5):2806. doi: 10.15829/1728-8800-2021-2806.</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">Ibáñez B. Myocardial infarction in times of COVID-19. Rev Esp Cardiol (Engl Ed). 2020;73(12):975–977. doi: 10.1016/j.rec.2020.09.023.</mixed-citation><mixed-citation xml:lang="ru">Ibáñez B. Myocardial infarction in times of COVID-19. Rev Esp Cardiol (Engl Ed). 2020;73(12):975–977. doi: 10.1016/j.rec. 2020.09.023.</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><mixed-citation>Russo V, Cante L, Imbalzano E, Di Micco P, Bottino R, Carbone A, D'Andrea A. The Impact of COVID-19 Pandemic on Hospitalization and Interventional Procedures for Cardiovascular Diseases during the First Wave in Italy. Int J Environ Res Public Health. 2022;20(1):472. doi: 10.3390/ijerph20010472.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Iannaccone M, Abdirashid M, Annone U, Saint-Hilary G, Meier P, Chieffo A, Chen S, di Mario C, Conrotto F, Omedè P, Montefusco A, De Benedictis M, Rettegno S, Doronzo B, Gasparini M, Rinaldi M, D'Amico M, D'Ascenzo F. Comparison between functional and intravascular imaging approaches guiding percutaneous coronary intervention: A network meta-analysis of randomized and propensity matching studies. Catheter Cardiovasc Interv. 2020;95(7):1259–1266. doi: 10.1002/ccd.28410.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Del Buono MG, Montone RA, Camilli M, Carbone S, Narula J, Lavie CJ, Niccoli G, Crea F. Coronary Microvascular Dysfunction Across the Spectrum of Cardiovascular Diseases: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021;78(13):1352–1371. doi: 10.1016/j.jacc.2021.07.042.</mixed-citation></ref></ref-list></back></article>
